Benjamin P. Levy, MD, on KRAS G12C–Mutated NSCLC: Current Treatment Landscape

Submitted by Anonymous on

Benjamin P. Levy, MD, on KRAS G12C–Mutated NSCLC: Current Treatment Landscape Thematic Newsreels Advertisement Benjamin P. Levy, MD, of Johns Hopkins Sidney Kimmel Cancer Center, reviews currently available therapies for patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC), noting...

Stephen Liu: High Response Rates for Frontline Ifebemtinib/Garsorasib in KRAS G12C NSCLC

Submitted by Anonymous on

Stephen Liu: High Response Rates for Frontline Ifebemtinib/Garsorasib in KRAS G12C NSCLC Stephen Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on shared...

Stephen Liu: High Response Rates for Frontline Ifebemtinib/Garsorasib in KRAS G12C NSCLC

Submitted by Anonymous on

Stephen Liu: High Response Rates for Frontline Ifebemtinib/Garsorasib in KRAS G12C NSCLC / cancer, Huaqiu Shi, Liming Zhu, Ling Zhang, Lung cancer, NSCLC, Stephen Liu/X Stephen Liu: High Response Rates for Frontline Ifebemtinib/Garsorasib in KRAS G12C NSCLC Stephen Liu, Director...

Can Precision Medicine Crack Another KRAS Code? New Study Targets a Rare Lung Cancer Mutation-but the Clinical Test Still Lies Ahead

Submitted by Anonymous on

A multinational research team led by Dr. William J. McDaid, Dr. Colin R. Lindsay, and Professor Angeliki Malliri at The University of Manchester and The Christie NHS Foundation Trust reports that KRAS G13C-mutant non-small cell lung cancer (NSCLC)-a previously untargetable...

InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation

Submitted by Anonymous on

NANJING, China, July 9, 2026 /PRNewswire/ — InxMed Co., Ltd (“InxMed”), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical results of ifebemtinib (IN10018), a highly selective focal adhesion kinase...

Divarasib Outperforms First-Gen Competitors in Pretreated KRAS G12C NSCLC

Submitted by Anonymous on

Genentech’s next-generation KRAS G12C inhibitor, divarasib, demonstrated superior survival outcomes over sotorasib and adagrasib in a head-to-head study, maintaining a manageable and consistent safety profile Topline data were announced from a head-to-head phase 3 trial evaluating divarasib vs first generation...

InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation

Submitted by Anonymous on

InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation PR Newswire NANJING, China, July 9, 2026 NANJING, China, July 9,...

InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation

Submitted by Anonymous on

This is a paid press release. Contact the press release distributor directly with any inquiries. InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC)...

Subscribe to Newsfeed